Learn the Role of Vyepti for Migraine Prevention
December 2022
Vyepti (eptinezumab) will be the latest CGRP antagonist to PREVENT migraine in adults.
It limits vasodilation by blocking calcitonin gene-related peptide (CGRP)...similar to Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab).
These CGRP antagonists lead to 1 or 2 fewer migraine days per month versus placebo. This seems similar to oral first-line options (beta-blockers, topiramate, valproate, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive